Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration

Toxicology Letters

Volumn 178, Issue 1, 2008, Pages 29-36

  Rohanová, Miroslava ^a   Páleníček, Tomáš ^b   Balíková, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

2C B; 4 bromo 2,5 dimethoxyphenethylamine; Disposition; Metabolites; Pharmacokinetics; Rats

Indexed keywords

4 BROMO 2 HYDROXY 5 METHOXYPHENETHYLAMINE; 4 BROMO 2,5 DIMETHOXYPHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD BRAIN BARRIER; BRAIN; BRAIN TISSUE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; EXPERIMENTAL STUDY; KINETICS; LIPOPHILICITY; LIVER; LUNG PARENCHYMA; MALE; MASS FRAGMENTOGRAPHY; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TOXICITY; VALIDATION STUDY;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ADMINISTRATION, CUTANEOUS; ANIMALS; BRAIN; DIMETHOXYPHENYLETHYLAMINE; LIVER; LUNG; MALE; PSYCHOTROPIC DRUGS; RATS; RATS, WISTAR;

RATTUS;

EID: 41749090678     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.01.017     Document Type: Article

References (32)

1. Berankova K., Szkutova M., and Balikova M. Distribution profile of 2, 5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses. Forensic Sci. Int. 170 (2007) 94-99
2. Berankova K., and Balikova M. Study on metabolites of 2, 5-dimethoxy-4-bromamphetamine (DOB) in human urine using gas chromatography-mass spectrometry. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 149 (2005) 465-468
3. Carmo H., de Boer D., Remiao F., Carvalho F., dos Reys L.A., and de Lourdes Bastos M. Metabolism of the designer drug 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J. Chromatogr. B. 811 (2004) 143-152
4. Carmo H., Hengstler J.G., de Boer D., Ringel M., Remiao F., Carvalho F., Fernandes E., dos Reys L.A., Oesch F., and de Lourdes Bastos M. Metabolic pathways of 4-bromo-2, 5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 206 (2005) 75-89
5. Charalampous K.D., Walker K.E., and Kinross-Wright J. Metabolic fate of mescaline in man. Psychopharmacology (Berl) 9 (1966) 48-63
6. de Boer D., Reys L.A., Gijzels M., Pylon N., Bosman I.J., and Maes R.A.A. Studies on the metabolism of 2C-B. Proceedings of the 1998 joint SOFT/TIAFT. Newport Beach (1998) 352-354
7. de Boer D., Gijzels M.J., Bosman I.J., and Maes R.A.A. More data about the new psychoactive drug 2C-B. J. Anal. Toxicol. 23 (1999) 227-228
8. de Boer D., dos Reys L.A., Pylon N., Gijzels M., Bosman I.J., and Maes R.A.A. Preliminary results on the urinary excretion of 2C-B (4-bromo-2,5-dimethoxyphenethylamine) and its metabolites in humans. Br. J. Pharmacol. 127 (1999) 41P
9. de Boer D., and Bosman I.J. A new trend in drug-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm. World Sci. 26 (2004) 110-113
10. Ewald A.H., Fritschi G., Bork W.R., and Maurer H.H. Designer Drugs 2, 5-dimethoxy-4-bromo-amphetamine (DOB) and 2, 5-dimethoxy-4-bromo-methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 41 (2007) 487-496
11. Giroud C., Ausburger M., Rivier L., Mangin P., Sadeghipour F., Varesio E., Veuthey J.L., and Kamalaprija P. 2C-B: a new psychoactive phenylethylamine recently discovered in ecstasy tablets sold on the Swiss black market. J. Anal. Toxicol. 22 (1998) 345-354
12. Glennon R.A., and Anderson G.M. Serotonin receptor affinities of psychoactive phenalkylamine analogues. J. Med. Chem. 23 (1980) 294-299
13. Glennon R.A., Titeler M., and Lyon R.A. A preliminary investigation of the psychoactive agent 4-bromo-2, 5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol. Biochem. Behav. 30 (1988) 597-601
14. Glennon R.A., Raghupathi R., Bartyzel P., Teitler M., and Leonhardt S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem. 35 (1992) 734-740
15. Kanamori T., Inoue H., Iwata Y., Ohmae Y., and Kishi T. In vivo metabolism of 4-Bromo-2, 5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J. Anal. Toxicol. 26 (2002) 61-66
16. Kanamori T., Tsujikawa Y., Ohmae Y., Iwata Y., Inoue H., Inouye Y., and Kishi T. Excretory profile of 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in rat. J. Health Sci. 49 (2003) 166-169
17. Kanamori T., Tsujikawa Y., Ohmae Y., Iwata Y., Inoue H., Kishi T., Nakahama T., and Inouye Y. A study of the metabolism of methamphetamine and 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Forensic Sci. Int. 148 (2005) 131-137
18. Karch S.B. Karch's pathology of drug abuse. In: Karch S.B. (Ed). Hallucinogens (2002), CRC Press, Boca Raton 287
19. Laing R.R., and Siegel J.A. Hallucinogens. A forensic drug handbook. In: Laing R.R., and Seigel J.A. (Eds). Occurrences and Forms of the Hallucinogens (2003), Academic Press, Amsterdam 58-59
20. Laing R.R., and Siegel J.A. Hallucinogens. A forensic drug handbook. In: Laing R.R., and Seigel J.A. (Eds). Basic Pharmacology and Effects (2003), Academic Press, Amsterdam 82
21. Lobos M., Borges Y., Gonzalez E., and Cassels B.K. The action of the psychoactive drug 2C-B on isolated rat thoratic aorta. Gen. Pharmacol. 23 (1992) 1139-1142
22. Moffat A.C., Osselton M.D., and Widdop B. Clarke's Analysis of Drugs and Poisons (2004), Pharmaceutical Press, London
23. Monte A.P., Marona-Levicka D., Parker M.A., Wainscott D.B., Nelson D.L., and Nichols D.E. Dihydrobenzofuran analogues of hallucinogens. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem. 39 (1996) 2953-2961
24. Neuvonen K., Neuvonen H., and Fülöp F. Effect of 4-substitution on psychotomimetic activity of 2, 5-dimethoxy amphetamines as studied by means of different substituent parameter scales. Bioorg. Med. Chem. Lett. 16 (2006) 3495-3498
25. Peters F.T., and Maurer H.H. Bioanalytical method validation and its implications for forensic and clinical toxicology-a review. Accred. Qual. Assur. 7 (2002) 441-449
26. Peters F.T., Drummer O.H., and Musshoff F. Validation of new methods. Forensic Sci. Int. 165 (2007) 216-224
27. Sargent T., Kalbhen D.A., and Shulgin A.T. In vivo human pharmacodynamics of the psychodysleptic 4-Br-2, 5-dimethoxyphenylisopropylamine labelled with 82Br or 77Br. Neuropharmacology 14 (1975) 165-174
28. Scheline R.R. Mammalian Metabolism of Plant Xenobiotics. Metabolism of Amines, Nitriles, Amides and Non-protein Amino Acids (1978), Academic Press, London pp. 330-364
29. Shulgin A., and Carter M.F. Centrally active phenethylamines. Psychopharm. Commun. 1 (1975) 93-98
30. Shulgin A., and Shulgin A. PIHKAL-A Chemical Love Story (1991), Transform press, Berkeley
31. Theobald D.S., Fritschi G., and Maurer H.H. Studies on the toxicological detection of the designer drug 4-bromo-2, 5-dimethoxy-phenethylamine (2C-B) in rat urine using gas chromatographic-mass spectrometry. J. Chromatogr. B 846 (2007) 374-377
32. Villalobos C.A., Bull P., Saez P., Cassels K.P., and Huidobro-Toro J.P. 4-Bromo-2, 5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol. 141 (2004) 1167-1174